RecruitingPhase 2Drug trialStudy of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular DiseasesTo evaluate the safety, efficacy and tolerability of sparsentan oral suspension and tablets, and assess changes in proteinuria after once-daily dosing over 108 weeks.